

(I)

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein:

A^1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of C_{1-12}alkyl, C_{1-12}alkoxy, aryl and halogen or together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;

R^1 represents a hydrogen atom, [an] a C_{1-12}alkyl group, [an acyl group,] a C_{1-6}alkylcarbonyl group, [an aralkyl group,] an aryl-C_{1-12}alkyl group, an aryl-C_{1-12}alkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group, wherein any aryl group is phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C_{1-12}alkyl, hydroxy, amino, nitro, carboxy, C_{1-12}alkoxycarbonyl, C1-12alkoxycarbonyloxyC_{1-12}alkyl, C_{1-12}alkylcarbonyloxy, or a C_{1-12}alkylcarbonyl group;

R^2 and R^3 each represent hydrogen, or R^2 and R^3 together represent a bond;

A^2 represents a benzene ring having [in total up to five] three optional substituents which may be selected from halogen, substituted or unsubstituted C_{1-12}alkyl or C_{1-12}alkoxy, wherein the substituents for the alkyl group are selected from halogen, C_{1-12}alkyl, phenyl, C_{1-12}alkoxy, halo-C_{1-12}alkyl, hydroxy, amino, nitro, carboxy, C_{1-12}alkoxylcarbonyl, C_{1-12}alkylcarbonyloxy, or C_{1-12}alkylcarbonyl; and

n represents an integer in the range of from 2 to 6.